@Bioversys

BioVersys is a publicly listed Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets.

 Basel
bioversys.com
Joined August 2013
  • Tweets186
  • Following72
  • Followers425
33Media
Cutting-edge clinical development is in focus, starting with a new combination targeting A. baumannii, we'll move onto novel approaches addressing chlamydia infections and a brand-new antibiotic for treating UTIs. 🎥 Watch live now: portalapp.bsac.eventsair.com… #ACC2026 #AMR
1
2
1
3
159
🚀🔬Day 2 kicks off with Session Five at #ACC2026 Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice. 🎥 Join us live now: portalapp.bsac.eventsair.com… @Bioversys I @SSI_dk I @GSK #AMR #ClinicalDevelopment
1
2
1
6
289
BioVersys retweeted
Edison@Edison_Inv_ResFeb 11
BioVersys — Poised to unlock value in critical AMR BioVersys is focused on developing novel drugs to address antimicrobial resistance (AMR)… @Bioversys $BIOV 📖 Full analysis: edisongroup.com/research/poi…

BioVersys: poised to unlock value in critical AMR

BioVersys is focused on developing novel drugs to address antimicrobial resistance (AMR).

edisongroup.com
1
2
137
From @ETH lab to @sixgroup Swiss Exchange: the @Bioversys antibiotic revolution 🧬 top100startups.swiss/BioVers… From an ETH Zürich spin-off to a publicly listed biotech tackling antibiotic resistance, BioVersys AG exemplifies how Swiss science can transform global health. With CHF 130 million raised, two WHO-priority drug candidates, and a CHF 213 million valuation on the SIX Swiss Exchange, the company is redefining the future of antibiotics. 💊 🗣️ As Founder & CEO Marc Gitzinger shares: “A world without access to working antibiotics would lead to losing the last 50 years of medical progress.” Supported by @venturekick and Venture Leaders by Venturelab, BioVersys AG’s journey from a PhD project to clinical breakthroughs and global partnerships, shows the power of persistence, precision, and purpose in biotech innovation. 💡 Read how BioVersys is rebuilding the antibiotic pipeline and leading the charge against resistant bacteria. Make sure to follow @venturekick to stay up to date on the latest breakthroughs, and discover the early-stage Swiss startups shaping the future of innovation! #TOP100SSU #SwissStartups #Innovation #Entrepreneurship #StartupEcosystem
1
6
287
🎉 We're excited to announce that @Bioversys has been awarded with non-dilutive funding via our CDP programme to advance the pipeline of preclinical assets for CF lung infections. Read the press release ow.ly/rTUe50S8cEx @MedDiscCat | @cftrust | @lifearc1
2
1
1
10
831
CHF 12.3 million to boost novel drugs against tuberculosis: TOP 100 Swiss scale-up @Bioversys secures its Series C and expands collaboration with GSK. Congrats to the world-class team led by biotech pioneers Marc Gitzinger, Sergio Lociuro, and Glenn Dale! venturekick.ch/BioVersys-str…
2
1
8
596
On Friday @koutterson and I sat down to marvel at all the amazing events that have happened recently in the #AMR world. Truly astonishing stuff! #StopSuperbugs #SquashSuperbugs #AMRSOS #FireExtinguishersOfMedicine 💊🧯⚕️ youtu.be/dD1byEoP8t8
8
1
21
1,532
Marc Gitzinger, BEAM Alliance: 83 % der Antibiotika-Projekte werden derzeit von kleinen Unternehmen durchgeführt, meist in frühen Stadien. Es braucht dringend neue Vergütungsmöglichkeiten, die es ermöglichen, dass auch große Pharmaunternehmen dazustoßen. @vfa_pharma @BPI_Pharma
1
1
7
Die Covid-Pandemie bindet viel Aufmerksamkeit. Doch auch die stille Pandemie der multiresistenten bakteriellen Infektionen muss angegangen werden. Daher heute eine Veranstaltung in Berlin von @vfapharma, @BPI_Pharma und dem Dt. Netzwerk gegen Antimikrobielle #Resistenzen (DNAMR).
1
2
17
We keep working to provide new antibiotics for hospital patients, to ensure the developments of our modern healthcare systems are protected, and we are grateful to have great support from @CARB_X! lnkd.in/dyBsRCn

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
3
5
BioVersys retweeted
CARB-X@CARB_X1 Jun 2021
*NEWS* - @CARB_X funds @Bioversys🇨🇭to develop pyrrolocytosines to treat severe infections, inc pneumonia, caused by #antibiotic-resistant ESKAPE bacteria. New class. 2nd BioVersys project funded ☞ carb-x.org/BioVersys2 ☜ @BARDA @PHEgov @Wellcome_AMR @BU_tweets #superbugs
11
22
USD 15.3 Million to fight life-threatening resistant bacteria, to save lives: @BioVersys wins the support of the @CARB_X accelerator at Boston University. Founder Marc Gitzinger: "Switzerland remains amongst the top global biotech innovators." venturekick.ch/BioVersys-get… #VentureKick
1
7
18
A major success story in Swiss biotech: TOP 100 Swiss Startup Awards winner @BioVersys raises EUR 20 Million from the @EIB! A big applause for the fantastic team of Venture Leader Marc Gitzinger - keep excelling!!! #TOP100SSU #VLeadersBiotech #VLeadersChina
Venture Kick
@venturekick14 Apr 2021
EUR 20 Million to fight life-threatening resistant bacterial infections: @BioVersys is the first Swiss biotech company to receive a venture loan from the European Investment Bank. Applause for founder Marc Gitzinger and his excellent team! venturekick.ch/BioVersys-rec… #VentureKick
3
7
EUR 20 Million to fight life-threatening resistant bacterial infections: @BioVersys is the first Swiss biotech company to receive a venture loan from the European Investment Bank. Applause for founder Marc Gitzinger and his excellent team! venturekick.ch/BioVersys-rec… #VentureKick
2
1
8
Did you know that 1.7 billion people worldwide carry tuberculosis? Venture Leader Marc Gitzinger with his team at TOP 100 Swiss startup @BioVersys is fighting against the disease, now granted EUR 2.7 million from the EU: venturelab.ch/BioVersys-TASK… #TOP100SSU #VLeadersChina
2
9
BioVersys retweeted
bEto-TB@bEtoTB124 Feb 2021
BioVersys, @taskapplied, and @GSK have been awarded 2.7 million Euro from EDCTP for the further development of BVL-GSK098 with ethionamide in a Phase 2a TB study. #bEtoTB #Tuberculosis #ClinicalTrials #Phase2 #GlobalHealth #PublicPrivatePartnership linkedin.com/posts/bioversys…
2
2
According to @pewtrusts, over 95% of the antibiotics in development today are being studied by small companies. Nearly 75% of these are considered pre-revenue, meaning that they have no products on the market. Support is urgent for SMEs in the field of AMR. @EUScienceInnov
10
14
Join us tomorrow for the launch of a major initiative to take on the antibiotic innovation challenge, with Florence Séjourné, CEO @DaVolterra and President of AllianceBEAM More info here -> bit.ly/2ZykNQ6
7
11
Top 100 Swiss Startup, Venture Leaders and Venture Kick alumni BioVersys AG wins up to $8.92 million from CARB-X to develop anti-microbial resistance drugs. We interviewed CEO Marc Gitzinger: bit.ly/34fxekB #top100SSU
2
1
6
BioVersys retweeted
TRIC-TB@TRIC_TB23 Oct 2019
Article in German Handelsblatt on the need of new Antibiotics and the urgency for that policy makers change the reimbursement for these life saving drugs. linkedin.com/posts/alina-lun…
2
2
Load more